{'fraction_non_alphanumeric': 0.04095351362531672, 'fraction_numerical': 0.02869848492683179, 'mean_word_length': 4.899938987187309, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cryoballoon ablation for paroxysmal atrial fibrillation in Japan: 2-year safety and efficacy results from the Cryo AF Global Registry

Purpose Catheter ablation is a recommended rhythm control therapy after failed or intolerant antiarrhythmic drug (AAD) treatment for patients with atrial fibrillation (AF). This study evaluates clinical performance and safety of pulmonary vein isolation (PVI) using the cryoballoon (Arctic Front Advance) in Japan. Methods Cryo AF Global Registry is a prospective, multi-center registry. Patients with paroxysmal AF (PAF) were treated at 10 Japanese hospitals. Efficacy was evaluated by freedom from a ≥ 30-s recurrence of AF/atrial flutter (AFL)/atrial tachycardia (AT), AF-related symptoms, and quality of life using the EQ-5D-3L questionnaire. The safety endpoint was serious device- and procedure-related adverse events. Results The study included 352 patients with PAF (65 ± 10 years of age, 36% female, 36% without prior failure of AAD). Mean duration since first diagnosis of AF was 3.0 ± 5.5 years. Serious device- and procedure-related adverse event rate was 2.6% (95% CI: 1.2–4.8%). Freedom from AF/AFL/AT was 88.5% (95% CI: 84.7–91.4%) at 12 months and 86.7% (95% CI: 81.1–90.8%) at 24 months. The number of patients with ≥ 1 AF symptom was significantly decreased from 88% at enrollment to 22% (p < 0.01) at 12-month follow-up. General quality of life using EQ-5D did not improve significantly after 12 months in the summary score. However, in the visual analog scale score, there was improvement (5.8 ± 18.4; p < 0.01). Conclusions This study demonstrates that cryoablation used for PVI is a safe and effective treatment in real-world use for patients with PAF in Japan. Supplementary Information The online version contains supplementary material available at 10.1007/s10840-022-01132-0.


Introduction
The Arctic Front Advance (Medtronic, Inc.) cryoballoon ablation system was first approved for the treatment of patients with antiarrhythmic drug (AAD)-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation (AF) in Japan in 2014. Subsequently, the Cryo-Japan Post-Market Surveillance (PMS) study confirmed the short-term efficacy and safety of the cryoablation system for the treatment of patients with paroxysmal AF (PAF) in routine clinical practice [1]. As noted in the recent report from the Japanese Catheter Ablation Registry, AF catheter ablation accounted for nearly two-thirds of cardiac ablation procedures in 2018. Yet, reports of midand long-term outcomes of cryoballoon ablation for the treatment of patients with AF in Japan are limited [2]. In this report from the Cryo AF Global Registry, real-world efficacy, safety, and quality of life (QoL) outcomes in AF patients treated with the cryoballoon catheter in Japan are reported.

Study design
The Cryo Global Registry (ClinicalTrials.gov registration: NCT02752737) is an ongoing prospective, multi-center, observational, post-market study. The objectives of this sub-analysis were to evaluate acute procedural characteristics, safety, and efficacy when using the cryoballoon ablation catheter to treat patients with AF in Japan. Data were collected at ten hospitals in Japan (Supplemental Table S1). The study was conducted according to Good Clinical Practices (in compliance with local regulations and in accordance with the principles outlined in the Declaration of Helsinki). Each site received approval by an independent ethics/institutional review board and obtained written informed patient consent for all patients prior to enrollment. This study was sponsored by Medtronic, Inc.

Patient population
All patients ≥ 18 years old with a planned procedure using the Medtronic cryoablation system were eligible for inclusion in the registry. The present examination includes patients with PAF that were enrolled and treated at study centers in Japan for initial catheter ablation of AF. Patients were classified as having PAF if they had an episode(s) of AF that terminated spontaneously or with intervention within 7 days of arrhythmia onset.

Cryoballoon ablation procedure
The cryoballoon ablation procedure was performed according to standard-of-care procedures, which have been previously described [3][4][5][6][7]. In brief, patients were sedated using general anesthesia or conscious sedation. In general, a dedicated, 15-F OD steerable sheath (FlexCath Advance Steerable Sheath; Medtronic, Inc.) was used to introduce a 28-mm cryoballoon ablation catheter (Arctic Front Advance; Medtronic, Inc.) into the left atrium (LA). The cryoballoon catheter was maneuvered in the LA either over a J-tip guidewire or a dedicated inner-lumen octopolar/decapolar circular mapping catheter (Achieve or Achieve Advance; Medtronic, Inc.). Before each ablation, the cryoballoon catheter was inflated and advanced toward the antral surface of the pulmonary vein (PV). Upon antral occlusion of the targeted PV, the cryoapplication was initiated. The number and duration of freezes per PV were determined by the physician. It was recommended to pace the right phrenic nerve during all right-sided cryoapplications to monitor phrenic nerve function during each freeze. Adjunctive imaging, intraprocedural esophageal temperature monitoring, additional ablation tools (e.g., focal cryoablation and radiofrequency catheter ablation), and/or adjunctive lesions applied to each patient were at the discretion of the operating physician. Patients were discharged from the hospital using local standard-of-care practices.

Patient follow-up
This analysis examined patients enrolled in Japan between February 2017, and October 2018. Patients were followed according to the center's standard-of-care protocols with a post-procedure visit required at 12 months after the index procedure. Additionally, a subset of sites continued patient follow-up until 24 months after the index procedure. Arrhythmia recurrence monitoring was not standardized by usage of a study protocol but could be conducted by any of the following methods, including electrocardiogram, Holter monitor, trans-telephonic monitor, insertable cardiac monitor, pacemaker, and/or implantable cardioverter defibrillator. Cardiovascular medications were assessed at discharge and 12 months, and general QoL was assessed by the EQ-5D-3L questionnaire at baseline and 12-month follow-up.

Endpoints
Primary efficacy was defined as freedom from a ≥ 30-s recurrence of AF, atrial flutter (AFL) and/or, atrial tachycardia (AT) following a 90-day blanking period (during which atrial arrhythmia recurrences did not count toward the primary efficacy endpoint). The primary safety endpoint was the combined serious device-and procedure-related adverse event rate. Serious adverse events were investigator and Medtronic classified (and included all events that led to death, a serious deterioration in health, hospitalization, or a medical intervention). Arrhythmia recurrences classified by the physician as serious and device-or procedure-related were included in the primary safety endpoint for this analysis. All adverse events were followed until the event was resolved; the event was unresolved with no further actions, or the patient exited the study. Ancillary objectives included patient baseline demographics, characterization of the cryoablation procedure, and QoL after cryoballoon ablation. QoL was assessed by the EQ-5D-3L questionnaire, a generic measure of health status consisting of two parts. The first part assesses health in five dimensions (mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression) each of which has three levels of response. A summary score or health state index based on the 5 dimensions ranges from 0 (least healthy) to 1 (most healthy). The second part of the questionnaire consists of a visual analog scale (EQ VAS) on which the patient rates his or her perceived health from 0 (worst) to 100 (best).

Statistical analysis
Baseline characteristics and clinical data were summarized using the appropriate summary statistics. Continuous variables were summarized as mean and standard deviation, and categorical variables were summarized as counts and percentages. Kaplan-Meier methods were used to estimate the 12-and 24-month freedom from atrial arrhythmia recurrence and the primary safety adverse event rate. Standard error was calculated with Greenwood's formula. EQ-5D was scored using a Japanese value set [8]. Changes in QoL from baseline to 12 months were assessed with a Student's t-test. Changes in symptoms were assessed with McNemar's test. Values of P < 0.05 were considered significant. Statistical analyses were conducted using the SAS software version 9.4 (SAS Institute, Cary, North Carolina).

Patient disposition and characteristics
Between February 2017, and October 2018, 352 eligible patients underwent a cryoballoon ablation index procedure. Expected follow-up duration was 12 (n = 294) or 24 months (n = 58) based on the enrolling center ( Fig. 1). During follow-up, 25 of the 352 (7.1%) patients exited early for the following reasons, including: one patient was withdrawn by the investigator, 20 were lost to follow-up, and 4 patients requested a withdrawal. Standard of care visits before the required annual visit were performed in 268 patients for 861 visits. Baseline patient characteristics are detailed in Table 1. On average, the cohort was 65 ± 10 years of age, 35.8% female, had a CHA 2 DS 2 -VASc score of 2.2 ± 1.6, and was diagnosed with AF for a mean of 3.0 ± 5.5 (median of 0.7; IQR 0.3-3.4) years. All patients were diagnosed with PAF, and 36.4% of patients were deemed non-drug refractory as they had not failed a Class I or III AAD prior to the cryoablation procedure. Five patients had a prior catheter ablation for AFL (1.4%). All other patients were naïve to cardiac catheter ablation for atrial arrythmia and were undergoing an index ablation procedure.

Procedural characteristics
Procedure-related data are detailed in Table 2. Non-general anesthesia was utilized in 89.2% of procedures. All patients were treated with the 28-mm Arctic Front Advance (secondgeneration) cryoballoon. Preprocedural imaging with MRI or CT was performed in 46.3% of patients, and intraprocedural 3D electroanatomical mapping was performed in 36.4% of procedures. Phrenic nerve function was monitored during index ablation in 100% of procedures with a "pace and palpate" technique employed in 77.6% of cases. Esophageal temperature was monitored in 92.0% of the index procedures. The mean total procedure duration was 73 ± 26 min, mean LA dwell time was 45 ± 19 min, and average fluoroscopy time was 48 ± 36 min.
Overall, 95.7% of patients had all targeted PVs acutely isolated during the index procedure. The average number of freezes per PV was 1.3 ± 0.7 for a mean duration of 172 ± 44 s. The mean balloon nadir temperature during

Safety
Of the 352 patients, nine serious device-or procedurerelated events in nine patients occurred. The serious deviceand procedure-related adverse event rate was 2.6% (95% CI: 1.2-4.8%). Phrenic nerve injury (PNI) occurred in seven patients, and all PNI events were ongoing at the time of hospital discharge. Of the seven total PNI events, three PNIs (43%) were symptomatic as reported by the patient, and three PNIs (43%) were classified as a serious adverse event (Table 3). Within the 12-month follow-up, six patients had resolved their PNI with no further clinical sequelae, and one patient remained unresolved. No atrioesophageal fistula, pericardial tamponade, or PV stenosis was reported over the 24-month follow-up period. A full list of serious device-or procedure-related adverse events is provided in Table 3. No deaths related to the cryoablation occurred; however, there were two deaths that were not procedure-related (due to leukemia and heatstroke) during the follow-up period.

Efficacy
Patients were monitored for an arrhythmia recurrence during follow-up by the following methods and frequencies, including, 12-lead ECG used in 303 (86.1%) patients during 1049 visits and Holter monitoring or more continuous monitoring used in 180 (51.1%) patients during 326 visits. A comprehensive overview of all follow-up visits with monitoring can be found in the Supplemental Table S2. The 12-month Kaplan-Meier estimate of freedom from a ≥ 30-s recurrence of AF/AFL/AT was 88.5% (95% CI: 84.7-91.4%) at 12 months and 86.7% (95% CI: 81.1-90.8%) at 24 months (Fig. 2). Irrespective of arrhythmia recurrence, the number of patients on class I/III AADs reduced from 18.5% at the index procedure discharge to 13.2% at the 12-month followup with further reductions at the 24-month follow-up (with 5.5% on AAD therapy). A repeat ablation was performed in 25 (7.1%) patients during the 12-month follow-up, one of which was a repeat cryoballoon ablation performed during the 90-day blanking period (Table 4). After the 12-month follow-up period, one patient received a repeat ablation, and no patient had a third catheter ablation procedure during this study period.

Discussion
This analysis from the prospective, multi-center Cryo Global Registry evaluated the clinical performance and safety of the Arctic Front Advance cryoballoon in Japan. The serious device-and procedure-related adverse event rate was 2.6% after 24 months. Freedom from AF/AFL/ AT was 88.5% at 12 months and 86.7% at 24 months. The number of patients with ≥ 1 AF symptom had significantly decreased from 88% at enrollment to 22% at the 12-month follow-up. The more general, non-AF specific, EQ-5D summary score did not improve significantly while the EQ VAS score was significantly improved by 5.8 ± 18.4 scores after 12 months. These real-world results demonstrated that cryoablation was safe and effective for the treatment of patients with PAF in Japan. Importantly, contemporary procedural characteristics of cryoablation in Japan were observed within this registry. Adjunctive preprocedural imaging and intraprocedural mapping and monitoring were frequently performed during the cryoablation procedures. Furthermore, non-PVI lesions were commonly delivered (41.8%), with 34% of patients receiving a CTI linear ablation. History of atrial flutter was documented in 7.1% of the patients, and it is unknown whether atrial flutter was induced during electrophysiology testing in additional patients because of the limitations of data collection within this registry. Corroborating this observation, a high rate of CTI ablation was recently reported in a large retrospective study from Japan [9]. Also, PV potentials were 1 All targeted pulmonary veins isolated   monitored during the cryoapplication in 80.7% of patients, and on average, one cryoapplication was delivered to each PV for a median of 180 s. This observation indicates a shift in dosing strategy since the CRYO-Japan PMS study in which two applications were delivered per PV for approximately 150 s on average [1]. Since the PMS study, procedural best practices have been established to optimize PVI delivered by the Arctic Front Advance system through cryoballoon positioning techniques and freeze-tailored dosing based on PV potential monitoring [7,10,11]. Furthermore, procedure times were short at 73 min (compared to 150 min in the Japan PMS study). The short procedure times observed in the Japan Cryo Registry may be related to increased usage of tailored dosing paradigms and increased operator experience (since the cryoballoon catheter was first introduced in Japan). Additionally, the low AF/AFL/AT recurrence rate of 1.8% starting from 12 until 24 months compared to the 11.5% recurrence from end of the blanking period until the 12-month follow-up demonstrates an excellent longer-term lesion durability of the Arctic Front Advance cryoballoon using procedural best practices in Japan.
The procedure-and device-related serious adverse event rate was low in this study (2.6% after 24 months). While PNI was the most frequently observed adverse event in this cohort, the total number of serious and non-serious PNI events (7 in total) and the single PNI event ongoing at 12 months (0.3%) are in agreement with other recent studies [3,9,12]. Moreover, the rate of PNI in this current study is lower than older studies using the first-generation cryoballoon [4]. The short-term, 6-month efficacy of Arctic Front Advance cryoballoon ablation (for the treatment of patients with PAF conducted according to real-world practice across 33 centers after the initial approval of the cryoablation catheter in Japan in 2014) was 88.4% [1]. In this registry, the real-world freedom from atrial arrhythmia reoccurrence at 24 months was 86.7% with a low rate of repeat ablation over the follow-up period. These 24-month results are similar to the efficacy in patients with PAF in other contemporary registries that have followed patients after typical clinical practices in Europe and the USA [13][14][15][16]. Furthermore, AF-related symptoms were significantly reduced by 75% between baseline and 12 months with only 22% of patients  Table 5 Quality of life as measured by EQ-5D-3L 1 Of the 352 patients in the Efficacy Analysis Cohort, 326 completed a 12-month visit, of which 321 completed an EQ-5D questionnaire at both baseline and 12 months 2 t-test 3 Summary index score ranging from 0 to 1.00 with higher scores indicating a better health-related quality of life 4 A vertical visual-analog scale on which patients provide a global assessment of their health, ranging from 0 to 100, with higher scores indicating a better health related quality of life reporting AF-related symptoms at 12 months. QoL (as measured by the summary score of the EQ-5D-3L) was high at baseline and a non-significant trend in improvement was observed at 12 months; however, the respondents self-rated health measured by the EQ VAS reporting improved significantly. As symptom reduction is a primary objective in this patient population [17][18][19], these results support the utility of cryoablation for patients with symptomatic PAF in Japan.

Limitations
This sub-analysis of the observational Cryo Global Registry describes the clinical performance and safety of patients treated with Arctic Front Advance in Japan according to real-world clinical usage. Arrhythmia monitoring was performed to the standard-of-care methods at each site. At 12 months follow-up, data for monitoring beyond ECG was only available in 1/3 of the patients; however, at 24 months follow-up, data for monitoring was present in nearly 2/3 of the patients. Therefore, episodes of asymptomatic AF might not have been uniformly identified, but the longer-term efficacy data is supported by vigilant arrhythmia monitoring of patients. QoL with the EQ-5D summary score at baseline in this cohort was 0.917 (with a maximal score of 1). Consequently, improvements in QoL may not have been detectable with the EQ-5D-3L summary score (a more generalized tool) in this cohort. Finally, not all patients were followed up for > 12 months as an initial protocol, and only a limited number of patients were studied for a longer-term outcome.

Conclusions
This study demonstrates that PVI with the Arctic Front Advance cryoballoon catheter is a safe and effective treatment in the real-world clinical usage for patients suffering from symptomatic PAF in Japan.